Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review.
Therapeutic Advances in Psychopharmacology January 1, 2023 Vivian W. L. Tsang, Brendan Tao, Shannon Dames et al. 19 citations
A retrospective chart review of 128 participants in a 12-week ketamine-assisted group therapy program found that the treatment was well tolerated, with no dropouts. Across 448 sessions, elevated blood pressure occurred after 49.16% of sessions, while nausea affected 12.05% of participant-sessions, vomiting 2.52%, headache 3.35%, and dizziness in seven participant-sessions. Adverse events were transient and resolved with rest or medication. The findings suggest good safety and tolerability for intramuscular and sublingual ketamine dosing in a community group psychotherapy setting.